| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $83,781,828 ) (Continued on the next page) |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 001 | 21 | NIH | 3/31/2026 | $764,777 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35HL171556 | Promoting T cell reconstitution after hematopoietic cell transplantation | 001 | 3 | NIH | 3/27/2026 | $35,867 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM153148 | Investigating the chromatin landscape of complex tissues through cell-type-specific patterns | 001 | 3 | NIH | 3/27/2026 | $1,308 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM163369 | Deconvoluting disparate roles of DDX6 in translational control | 000 | 1 | NIH | 1/22/2026 | $75,052 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM163369 | Deconvoluting disparate roles of DDX6 in translational control | 001 | 1 | NIH | 1/22/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI171186 | Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses | 000 | 4 | NIH | 3/9/2026 | $857,757 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA262556 | Expanding the cancer paralog genetic interaction map to enable precision oncology | 000 | 3 | NIH | 2/26/2026 | $530,439 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM161275 | Mechanisms of Dynamic Cytoskeleton and Membrane Interactions | 000 | 1 | NIH | 2/27/2026 | $613,838 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R21AI190571 | Statistical Methods for Assessing Immune Correlates of Risk and Protection Using Flexible Two-Phase Sampling Designs that Enrich Longitudinal Samples | 000 | 1 | NIH | 2/9/2026 | $220,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U19AI174242 | Self-amplifying mRNA-based vaccines to elicit VRC01-class bnAbs | 000 | 4 | NIH | 2/19/2026 | $1,583,952 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 001 | 21 | NIH | 3/3/2026 | $0 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UH3DA057032 | ACT on Vaping: Digital Therapeutic for Young Adult Vaping Cessation | 001 | 4 | NIH | 2/24/2026 | $812,783 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM139429 | Molecular mechanisms and functions of global chromatin control | 002 | 7 | NIH | 2/24/2026 | $813,090 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA295226 | Optimizing pre-analytical variables for reliable mass spectrometry-based quantification of immunomodulatory proteins in cerebrospinal fluid in pediatric neuro-oncology trials | 000 | 2 | NIH | 3/3/2026 | $405,509 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM144128 | Data analysis tools for leveraging massive public data to improve hypothesis-driven research | 000 | 6 | NIH | 2/23/2026 | $431,963 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA287013 | Statistics and Data Management Center (SDMC) for the NCI Cancer Screening Research Network (CSRN) | 000 | 3 | NIH | 1/13/2026 | $1,346,937 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068617 | SDMC: HIV Prevention Trials Network | 000 | 21 | NIH | 1/10/2026 | $10,875,343 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 6 | NIH | 1/15/2026 | $125,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI167004 | In Vivo Gene Editing of B cells with NICE-AAV Vectors | 000 | 6 | NIH | 1/15/2026 | $574,738 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32HD113384 | Developmental mechanisms specifying vagal innervation of organ targets | 000 | 3 | NIH | 1/9/2026 | $80,224 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UG1CA286954 | NCI Cancer Screening Research Network: Coordinating and Communication Center | 000 | 3 | NIH | 1/15/2026 | $1,354,658 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | F32GM153148 | Investigating the chromatin landscape of complex tissues through cell-type-specific patterns | 000 | 3 | NIH | 1/19/2026 | $78,040 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 000 | 21 | NIH | 1/14/2026 | $17,863,384 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 000 | 21 | NIH | 1/14/2026 | $250,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI068614 | CoVPN 3008 - Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern | 000 | 21 | NIH | 1/14/2026 | $500,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | U01CA214057 | Developing CVD prediction models for women with early stage breast cancer | 000 | 6 | NIH | 1/19/2026 | $648,055 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA114536 | Novel synthetic receptors with improved antigen specificity and specificity for cancer therapy | 000 | 21 | NIH | 12/16/2025 | $392,157 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI179712 | Metabolite- and cytokine-mediated signals interact to control human CD8 T cell responses in tissues | 000 | 2 | NIH | 1/10/2026 | $849,176 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI136946 | Mechanisms and consequence of helical shape generation in Helicobacter pylori | 000 | 9 | NIH | 1/30/2026 | $578,926 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI165821 | Forecasting influenza evolution on a heterogeneous immune landscape | 000 | 5 | NIH | 1/29/2026 | $744,369 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI183406 | Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting | 000 | 3 | NIH | 2/24/2026 | $841,429 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177095 | Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | 000 | 3 | NIH | 1/30/2026 | $876,168 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI177078 | Statistical Methods for Advancing HIV Prevention | 000 | 4 | NIH | 1/30/2026 | $419,125 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R13AI189265 | Flow Cytometry Workshops in Africa | 000 | 2 | NIH | 1/14/2026 | $69,132 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI176563 | Deeply analyzing MHC class I-restricted peptide presentation mechanistics across alleles, pathways, and disease coupled with TCR discovery/characterization | 000 | 4 | NIH | 1/17/2026 | $804,206 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI175535 | Defining Protective CMV Immunity after Transplantation | 000 | 4 | NIH | 2/24/2026 | $774,089 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI178284 | Role of local antibodies in control of chronic genital herpes | 000 | 3 | NIH | 1/3/2026 | $865,722 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01AI170214 | Developing Durable, Env-Boosted CAR T Cells for HIV Cure | 000 | 4 | NIH | 11/27/2025 | $819,721 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM140823 | Mechanisms of transcriptional regulation and transcription factor specificity | 003 | 6 | NIH | 3/17/2026 | $1,105,868 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA286450 | Augmenting PSMA expression to enhance PSMA directed therapeutic efficacy | 000 | 3 | NIH | 2/17/2026 | $601,181 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA287573 | Interrogating roles for REST in small cell lung cancer therapy response and resistance | 000 | 3 | NIH | 12/8/2025 | $523,869 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | UM1AI069481 | Seattle Clinical Trials Unit | 000 | 21 | NIH | 12/9/2025 | $833,373 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01HL161037 | Longitudinal Impact of Respiratory Viruses on Bronchiolitis Obliterans Syndrome in Allogeneic Hematopoietic Cell Transplant Recipients | 000 | 6 | NIH | 2/12/2026 | $703,183 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R37CA234488 | Role of tumor cell cluster-induced signaling in breast cancer metastasis | 000 | 8 | NIH | 12/17/2025 | $362,340 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA298383 | Providing nicotine replacement therapy to enhance the efficacy of a smoking cessation smartphone app for Hispanic adults | 000 | 2 | NIH | 2/9/2026 | $647,926 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA277133 | Accelerating biomarker development through novel statistical methods for analyzing phase III/IV studies | 000 | 4 | NIH | 12/10/2025 | $361,548 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA276308 | Transcriptional-translational conflict in bladder epithelial homeostasis and cancer | 000 | 4 | NIH | 12/10/2025 | $512,155 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R35GM162410 | Visualization of native chromatin-associated complexes to elucidate chromatin regulatory mechanisms | 000 | 1 | NIH | 2/9/2026 | $484,000 |
| | 2026 | 2026 | FRED HUTCHINSON CANCER CENTER | 1100 FAIRVIEW AVE N | SEATTLE | WA | 98109-4433 | KING | USA | R01CA297681 | Statistical Methods for Precision Prevention | 000 | 2 | NIH | 12/5/2025 | $455,052 |
|
